EO decisions and CED recommendations (English, CSV)

EO decisions and CED recommendations: English CSV file you can open as a table, filter, chart and export up to 10,000 rows. From Government of Ontario, updated Jul 2026.

Format
CSV
Access
Table on demand (prepared when opened)
Publisher-reported update
2026-07-08

Information on drug funding decisions based on Executive Officer (EO) decisions and Committee to Evaluate Drugs (CED) recommendations. This information is intended for medical professionals and drug manufacturers.

Access original file

Data overview

Formats
CSV
File languages
English
Available actions
Explore table (prepared automatically) · Access original file

Sample rows

The first 10 rows, as CanQuery read them from the start of the publisher's file on 2026-11-01.

Generic NameBrand NameStrength (Format)ManufacturerReason for UseCED RecommendationDate ReviewedFunding Status* (Effective Date)
dalteparin sodium injectionFragmin3500 IU/0.28 mL (pre-filled syringe)Pfizer Canada Inc.AnticoagulantRecommended for funding13-Jan-16LU (March 30, 2016)
riociguatAdempas0.5 mg, 1 mg , 1.5 mg , 2 mg, 2.5 mgBayer Inc.Treatment of pulmonary arterial hypertension (PAH, WHO Group 1), as monotherapy or in combination with endothelin receptor antagonists, in adult patients (≥18 years of age) with WHO Functional Class …Not recommended for funding13-Jan-16Not funded
lisdexamfetamine dimesylateVyvanse10 mgShire Pharma Canada ULC• Attention Deficit Hyperactivity Disorder (ADHD). • Moderate to Severe Binge Eating Disorder (BED) in adultsRecommended for funding13-Jan-16GB (March 30, 2016)
apremilastOtezla10 mg ,20 mg ,30 mg (starter pack kit) 30 mgCelgene Inc.Psoriatic arthritisNot recommended for funding13-Jan-16Not funded
adalimumabHumira40mg/0.8 mL (subcutaneous solution)AbbVie CorporationWeekly dosing for the treatment of Crohn's disease.Not recommended for funding13-Jan-16Not funded
peginterferon beta- 1aPlegridy63 mcg/0.5 mL, 94 mcg/0.5 mL, 125 mcg/0.5 mLBiogen Canada Inc.Treatment of relapsing remitting multiple sclerosis (RRMS) for adult patients to reduce the frequency of clinical exacerbations and to slow the progression of disability.Not recommended for funding13-Jan-16EAP (March 13, 2017)
floxetine HClFluoxetine20 mgSanis Health Inc.AntidepressantRecommended for funding13-Jan-16GB (March 20, 2016)
tiotropium bromide monohydrate & olodaterol hydrochlorideInspiolto Respimat2.5 mcg & 2.5 mcg per actuationBoehringer Ingelheim Canada Inc.Chronic Obstructive Pulmonary Disease (COPD), including chronic bronchitis and emphysema.Recommended for funding13-Jan-16LU (March 30, 2016)
denosumabProlia60 mg/mLAmgen Canada Inc.Osteoporosis for men at high risk for fractureNot recommended for funding13-Jan-16LU (February 29, 2012)

Official sources and licences

Related open data